METTL13: A Protein Involved in Intracellular Signaling and Potential Drug Targets

Target Name: METTL13

NCBI ID: G51603

METTL13

METTL13: A Protein Involved in Intracellular Signaling and Potential Drug Targets

METTL13 (also known as DFNB26M) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the metal transmembrane protein family, which includes proteins that are involved in the regulation of ion transport and signaling.

One of the unique features of METTL13 is its ability to interact with various signaling molecules, including cAMP, PKA, and CREB-1. This suggests that METTL13 may be involved in the regulation of a wide range of cellular processes, including intracellular signaling, cell signaling, and inflammation.

In addition to its potential role in cellular signaling, METTL13 is also of interest as a potential drug target. Its interaction with cAMP and PKA, two molecules that are involved in the regulation of cell signaling, suggests that METTL13 may be a useful target for drugs that are designed to modulate cellular signaling pathways.

Furthermore, METTL13 has also been shown to be involved in the regulation of pancreatic function, including the production of insulin by beta cells and the regulation of pancreatic acid secretion. This suggests that METTL13 may be a useful target for drugs that are designed to modulate pancreatic function and potentially treat various diseases, such as diabetes.

In addition to its potential role in cellular signaling and pancreatic function, METTL13 is also of interest as a potential biomarker for various diseases. Its expression has been shown to be elevated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that METTL13 may be a useful biomarker for the diagnosis and treatment of these diseases.

Overall, METTL13 is a protein that is of interest as a potential drug target and biomarker. Further research is needed to fully understand its role in cellular signaling and its potential as a drug target and biomarker.

Protein Name: Methyltransferase 13, EEF1A Lysine And N-terminal Methyltransferase

Functions: Dual methyltransferase that catalyzes methylation of elongation factor 1-alpha (EEF1A1 and EEF1A2) at two different positions, and is therefore involved in the regulation of mRNA translation (PubMed:30612740, PubMed:30143613). Via its C-terminus, methylates EEF1A1 and EEF1A2 at the N-terminal residue 'Gly-2' (PubMed:30143613). Via its N-terminus dimethylates EEF1A1 and EEF1A2 at residue 'Lys-55' (PubMed:30612740, PubMed:30143613). Has no activity towards core histones H2A, H2B, H3 and H4 (PubMed:30612740). Negatively regulates cell proliferation at G1/S transition via transcriptional suppression of cell cycle regulatory genes such as CDK4 and CDK6 (PubMed:26763933)

The "METTL13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets